Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: Analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials

Clinical Drug Investigation

Volumn 31, Issue 1, 2011, Pages 51-60

  Papp, Kim A ^a   Signorovitch, James ^b   Ramakrishnan, Karthik ^b   Yu, Andrew P ^b   Gupta, Shiraz R ^c   Bao, Yanjun ^c   Mulani, Parvez M ^c  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab, therapeutic use; Psoriasis, treatment; Quality of life; Tumour necrosis factor receptor antagonists, therapeutic use.

Indexed keywords

ADALIMUMAB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; JOB PERFORMANCE; PAIN; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RISK ASSESSMENT; SHORT FORM 36; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 78149383500     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11539360-000000000-00000     Document Type: Article

References (38)

1. National Psoriasis Foundation. Statistics [online]. Available from URL: http://www.psoriasis.org/about/stats/ [Accessed 2009 Jun 5]
2. Stern RS,Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9
3. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21
4. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-92
5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370 (9583): 263-71
6. Hensler E, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6
7. de Jong EM. The course of psoriasis. Clin Dermatol 1997; 15: 687-92
8. Krueger GG. Psoriasis therapy: observational or rational? N Engl J Med 1993; 328: 1845-6
9. Spuls PI, Witkamp L, Bossuyt PM, et al. The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol 2004; 140: 338-44; discussion 344
10. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006; 54 (4 Suppl. 1): S171-81
11. Choi J, Koo JY. Quality of life issues in psoriasis. J AmAcad Dermatol 2003; 49 (2 Suppl.): S57-61
12. de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-7
13. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17: 24-8
14. Carrascosa JM, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006; 20: 840-5
15. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50
16. Saurat JH, Stingl G, Dubertret L, et al., CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66
17. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15
18. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-57
19. Flood J,Mihalik C, Fleming RR, et al. The use of therapeutic interchange for biologic therapies. Managed Care 2007; 16: 51-62
20. Horn EJ, Fox KM, Patel V, et al. Are psoriasis patients undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57 (6): 957-62
21. National Institute for Health and Clinical Excellence. Adalimumab for the treatment of psoriasis [technology appraisals TA146]. London: National Institute for Health and Clinical Excellence; 2008
22. Papp KA, Toth D, Rosoph L. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol 2006; 6: 9
23. Puig L, Roé E, García-NavarroX, et al. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clin Exp Dermatol 2009 Jun; 34 (4): 469-75
24. Feldman SR.A quantitative definition of severe psoriasis for use in clinical trials. Dermatolog Treat 2004; 15: 27-9
25. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-7
26. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18 (6): 341-50
27. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71
28. Fredriksson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44
29. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65
31. Ware JE, Snow KK, Kosinski MK, et al. SF-36 Health Survey: manual and interpretation guide. Boston (MA): The Health Institute, New EnglandMedical Center, 1993
32. Leary MR, Rapp SR, Herbst KC, et al. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 1998; 17: 530-6
33. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-7
34. Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-9
35. Cuchacovich R, Espinoza CG, Virk Z, et al. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol 2008 Dec; 14 (6): 353-6
36. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-a inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007 Feb; 143 (2): 223-31
37. Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? [published erratum appears in J Rheumatol. 2007 Dec; 34 (12): 2506]. J Rheumatol 2007 Feb; 34 (2): 434-7
38. Goiriz R, DaudénE, Pérez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007 Mar; 32 (2): 176-9